key: cord-0829190-8dsmw464
authors: Fix, Oren K.; Hameed, Bilal; Fontana, Robert J.; Kwok, Ryan M.; McGuire, Brendan M.; Mulligan, David C.; Pratt, Daniel S.; Russo, Mark W.; Schilsky, Michael L.; Verna, Elizabeth C.; Loomba, Rohit; Cohen, David E.; Bezerra, Jorge A.; Reddy, K. Rajender; Chung, Raymond T.
title: Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
date: 2020-04-16
journal: Hepatology
DOI: 10.1002/hep.31281
sha: f3faa4b5192cfcdd0555c6d8c4cf5c6a4a4eb767
doc_id: 829190
cord_uid: 8dsmw464

Coronavirus disease 2019 (COVID‐19), the illness caused by the SARS‐CoV‐2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS‐CoV‐2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID‐19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID‐19 pandemic on liver patients and healthcare providers.

The novel coronavirus SARS-CoV-2 is most similar to the beta-coronaviruses, SARS-CoV and MERS-CoV, the causative agents of the SARS outbreak in 2002-2003 and the MERS outbreak beginning in 2012, respectively. SARS-CoV-2 is a single, positive-stranded RNA virus that replicates using a virally encoded RNA-dependent RNA polymerase. SARS-CoV-2 binds to and is internalized into target cells through angiotensin-converting enzyme 2 (ACE2), which acts as a functional receptor. (8, 9) ACE2 is present in biliary and liver epithelial cells; therefore, the liver is a potential target for infection. (10) The incidence of elevated serum liver biochemistries in hospitalized patients with COVID-19 ranges from 14% to 53%. (1, (11) (12) (13) (14) (15) AST and ALT are primarily elevated in COVID-19, generally 1-2 times the upper limit of normal (ULN), with normal to modestly elevated total bilirubin levels early in the disease process. Liver injury occurs more commonly in severe COVID-19 cases than in mild cases, and rare cases of severe acute hepatitis have been described. (11, 15, 16) Liver injury in mild COVID-19 cases is usually transient and does not require specific treatment. (15) In addition to other markers of disease severity such as lymphopenia and D-dimer, low serum albumin on hospital admission is a marker of COVID-19 severity. (14, 17, 18) Severe COVID-19 is uncommon in children. (19, 20) In the rare cases of severe pediatric COVID-19, increases in ALT or AST, when present, are usually mild (<2x ULN). (19) Data from Bergamo, a major site of COVID-19 in Italy, showed no increase in hospitalization among >300 children followed for liver transplantation, autoimmune hepatitis, or hepatoblastoma. (20) In this report, 3 of 13 hospitalized children following liver transplantation or receiving chemotherapy for hepatoblastoma tested positive for SARS-CoV-2 and none developed clinical pulmonary disease. (20) Liver histologic assessment has been limited but thus far is nonspecific and ranges from moderate microvesicular steatosis with mild, mixed lobular and portal activity to focal necrosis. (21, 22) Elevated liver biochemistries may reflect a direct virus-induced cytopathic effect and/or immune damage from the provoked inflammatory response. (12, 23) Therapeutic agents used to manage symptomatic COVID-19 may be hepatotoxic, including remdesivir and tocilizumab. Less common causes of elevated liver biochemistries include chloroquine, hydroxychloroquine, and azithromycin.

It is unknown whether patients with chronic liver disease, especially viral hepatitis B and/or C, are more susceptible to liver damage from SARS-CoV-2, as was the case with SARS-CoV. (14) It is also unknown whether SARS-CoV-2 infection exacerbates cholestasis in those with underlying cholestatic liver disease such as primary biliary cholangitis or primary sclerosing cholangitis or with underlying cirrhosis. (15) Emerging data suggest that patients with nonalcoholic fatty liver disease (NAFLD) may be at higher risk for severe It is unclear if the risk is specific to NAFLD or to coexisting metabolic risk factors such as cardiovascular disease, diabetes mellitus, and obesity, which are known to be associated with COVID-19 severity. (25) It will be difficult to differentiate whether increases in liver biochemistries are due to SARS-CoV-2 infection itself; its complications, including myositis (particularly with AST>ALT), cytokine release syndrome, ischemia/hypotension; or a drug-induced liver injury. (15, 21) An approach to evaluating the patient with COVID-19 and elevated liver biochemistries is shown in Figure 1 .

 Patients with cirrhosis, those with autoimmune hepatitis on immunosuppressive medications, and posttransplant patients on immunosuppressant therapy should be considered to be at increased risk for severe COVID-19 and should be prioritized for testing until further data become available.

 Consider etiologies unrelated to COVID-19, including other viruses such as hepatitis A, B and C, when assessing patients with COVID-19 and elevated liver biochemistries.  To limit unnecessary transport of patients with COVID-19, ultrasound or other advanced imaging (e.g., MRI/MRCP) should be avoided unless it is likely to change management, e.g., clinical suspicion for biliary obstruction or venous thrombosis.

 Consider other causes of elevated liver biochemistries, including myositis (particularly when AST>ALT), cardiac injury, ischemia, and cytokine release syndrome.

 The presence of abnormal liver biochemistries should not be a contraindication to using investigational or off-label therapeutics for COVID-19 (e.g., remdesivir, tocilizumab, chloroquine, hydroxychloroquine), although AST or ALT levels >5x ULN may exclude patients from consideration of some investigational agents.

 Regular monitoring of liver biochemistries should be performed in all hospitalized COVID-19 patients, particularly those treated with remdesivir or tocilizumab, regardless of baseline values.  In patients with autoimmune hepatitis or liver transplant recipients with active COVID-19 and   elevated liver biochemistries, do not presume disease flare or acute cellular rejection without biopsy   confirmation.  Evaluate all children with elevated AST or ALT for underlying liver diseases and coexisting infections as COVID-19 is not commonly associated with abnormal liver biochemistries in children. (19)  Follow guidance in your clinical study protocol and/or by the Food and Drug Administration (FDA) for monitoring of liver biochemistries and discontinuation of study drug used to treat COVID-19.

Information is limited regarding the effects of SARS-CoV-2 in patients with chronic liver disease. Data from the CDC on 122,653 COVID-19 cases including 7,162 (5.8%) with data on underlying health conditions, showed that approximately one third of these patients (37.6%) had at least one underlying condition or risk factor for severe outcomes.(26) Among these patients with underlying conditions, only 41 patients (0.6%) had chronic liver disease, including 7 who required ICU admission. (26) Both immunocompetent and immunosuppressed patients can contribute to SARS-CoV-2 spread even if they are asymptomatic. (27) Children are less likely to become ill from SARS-CoV-2 infection but can still contribute to spread of the virus. (19) There is no evidence that patients with stable chronic liver disease due to hepatitis B and/or C, or cholestatic syndromes such as primary biliary cholangitis or primary sclerosing cholangitis have increased susceptibility to SARS-CoV-2 infection. (15) The effect of COVID-19 in patients with hepatocellular carcinoma (HCC) is not known. A case series reported an association between worse COVID-19 outcomes and a history of non-hepatic types of cancer.(28) Those who underwent recent chemotherapy had an even higher risk of severe COVID-19, but the series also included those without recent chemotherapy. (28) It is unknown whether patients with HCC are at increased risk for severe COVID-19 by virtue of their malignancy. The slow median doubling time of HCC supports a rationale of a short delay in radiological surveillance given the challenges many centers are currently facing with COVID-19. (29) 

This article is protected by copyright. All rights reserved

 The CDC has provided broad and comprehensive recommendations to limit face-to-face visits, optimize supply of personal protective equipment (PPE), clean and disinfect rooms or areas visited by individuals with suspected or confirmed COVID-19, and monitor healthcare workers for signs of illness. (3, 30) o Consider seeing in person only new adult and pediatric patients with urgent issues and clinically significant liver disease (e.g., jaundice, elevated ALT or AST >500 U/L, recent onset of hepatic decompensation).  Initiating treatment of hepatitis C in a patient with COVID-19 is not routinely warranted.

 Continue monitoring in those on or off therapy for HCC and continue surveillance in those at risk for HCC (cirrhosis, chronic hepatitis B) as close to schedule as circumstances allow, although an arbitrary delay of 2 months is reasonable.

o Discuss the risks and benefits of delaying surveillance with the patient and document the discussion.

 Review images of new referrals for patients with liver masses in tumor board or with expert radiologists in virtual multidisciplinary conference prior to scheduling an in-person visit.

 Consider virtual patient visits to discuss diagnosis and management of HCC and other liver tumors.

 Proceed with HCC treatments when able rather than delaying them due to the pandemic.

Information is limited regarding the effects of SARS-CoV-2 infection in patients with decompensated cirrhosis or those awaiting liver transplantation. The complex decision making involved in whether or not to proceed with transplantation is now significantly more challenging due to the COVID-19 pandemic. It is essential that Accepted Article transplant centers continuously assess their local situation and its impact on patients awaiting transplantation. Some transplant centers may decide that individual candidates should not receive organ offers at this time. Special consideration could be given to wait-listed patients with high model for end-stage liver disease (MELD) scores or HCC based on their risk of drop-out and disease progression. A reduction in organ recovery is expected because of COVID-19-related limitations on institutional resources and our evolving understanding of the risk of donor-derived disease transmission. These factors will have a significant impact on the transplant waiting list resulting in increased waiting times. Risk stratification is important to identify patients who need to be evaluated for transplantation or complete their evaluation during the COVID-19 pandemic, including patients with high MELD scores, risk of decompensation, or tumor progression.

 Limit the number of patients coming to clinic for transplant evaluations.

o Consider evaluating only patients with HCC or those patients with severe disease and high MELD scores who are likely to benefit from immediate liver transplant listing.

 Develop a policy to decide which listed patients need to be seen in person.

 Consider telemedicine alternatives in place of outreach clinics.

 Obtain labs and imaging only as clinically necessary.

o Patients should not be asked to update labs simply to update their MELD score. Recent Organ Procurement and Transplantation Network (OPTN) policy changes provide guidance on how to maintain candidate MELD when updated lab results are not obtained. (31)  Ensure that patients have refills available for essential medications. Provide prescriptions for 90-day supplies instead of 30-day supplies. Many insurance companies are waiving early medication refill limits. Consider using medication delivery services.

 Consider instructing patients to avoid attending in-person community recovery support meetings such as Alcoholics Anonymous and provide alternative telephone or online resources.

 Advise patients not to travel during the COVID-19 pandemic.

 Consider providing documentation to patients, providers, and organ procurement teams to ease essential travel where travel restriction policies are in place. 

 Consider using specific screening facilities and a "COVID-19-free" path through the hospital for transplantation candidates.

 Conduct patient transplant education and social work, dietitian, and financial consultations by video conference, telemedicine, or telephone whenever possible.

 Avoid multiple patients in one room for patient education.

o Consider developing internet-based education sessions for patients and family members that can be deployed either by in-room computers or at home prior to patient evaluation.

Resource utilization and ethical considerations are inherently tied to liver transplantation. This is a critical and challenging area for which protocols and policies need to be carefully considered and developed. There is no over-arching policy that can or should be applied to every transplant center; these issues will need to be discussed and developed locally ( Table 1) o Consider resource utilization including ICU beds, ventilators, PPE and supply of blood products (especially platelets and type-specific packed red cells) in the decision to proceed with liver transplantation.

o Account for local COVID-19 prevalence data when considering suspension of transplantation.  Consider notifying patients that the COVID-19 pandemic may impact their waiting time on the transplant list.

 Notify patients that family and visitor access may be limited or prohibited during their hospital stay.

 Screen potential donors for exposure and clinical symptoms/fever compatible with COVID-19 (regardless of test results or availability). (34) o Alternatives to PCR-based testing such as chest radiography may also be considered.  Screen potential recipients with an acceptable organ offer for COVID-19 symptoms/fever before they are called in from home for transplantation.

 When an organ offer becomes available, call in to the hospital potential transplant recipients at the latest possible time to minimize exposure to the hospital environment. o Review as much donor history as possible for fever, respiratory symptoms, and radiographic findings.

 Consider having backup transplant recipients wait at home or away from the transplant center.

 Consider suspending living donor liver transplant programs during the pandemic, except for pediatric patients with acute liver failure. (34)  See the latest updates regarding COVID-19 related OPTN policy changes. (31)  An approach to liver transplant organ offers is shown in Figure 2 .

Data suggest that the immune response may be the main driver for pulmonary injury due to COVID-19 and that immunosuppression may be protective. (13, 20 

This article is protected by copyright. All rights reserved o An approach to managing liver transplant recipients with COVID-19 is shown in Figure 3 .  Initiate immunosuppressive therapy in patients with liver disease with or without COVID-19 who have strong indications for treatment (e.g., autoimmune hepatitis, graft rejection).

 In patients with COVID-19, use caution in initiating prednisone, prednisolone, or other immunosuppressive therapy where the potential benefit might be outweighed by the risks (e.g., alcohol-associated hepatitis).

Healthcare workers and other hospital staff are at risk for COVID-19. 

This article is protected by copyright. All rights reserved 

There currently are no FDA-approved therapies to prevent or treat COVID-19 infection. Many investigational or off-label therapeutics for COVID-19 may be hepatotoxic ( Table 2 ). An open-label, randomized, controlled trial of lopinavir-ritonavir vs. standard of care in adults hospitalized with severe COVID-19 showed no clinical benefit. (38) Treatment was stopped early in some patients taking lopinavir-ritonavir due to adverse events.

Ritonavir is a potent inhibitor of CYP3A4, which is involved in the metabolism of calcineurin inhibitors, sirolimus, and everolimus. The use of ritonavir requires a reduction in the tacrolimus dosage to 1/20-1/50 of baseline due to this drug-drug interaction.

This article is protected by copyright. All rights reserved Remdesivir is a nucleotide analogue with demonstrated activity against SARS-CoV and MERS-CoV in cultured cells, mice and non-human primates, and more recently against SARS-CoV-2 in human cell lines. (39, 40) Remdesivir is being tested in hospitalized patients with moderate to severe COVID-19 in randomized controlled trials and data from compassionate use have reported promising results. (41) (42) (43) Drugs that target the IL-6 receptor are being tested only in hospitalized patients with moderate to severe COVID-19.

Hydroxychloroquine (an analogue of chloroquine with a better safety profile) has been shown to have anti-SARS-CoV-2 activity in vitro. (44) A single-arm study from France of 20 patients with COVID-19 who were treated with hydroxychloroquine with or without azithromycin compared to 16 nonrandomized controls reported negative nasopharyngeal swabs for SARS-CoV-2 PCR in 70% of the treated group compared to 12.5% of the controls.(45) A separate study from France reported that the combination of hydroxychloroquine and azithromycin was not associated with clinical recovery or viral clearance and 4 of the 11 patients discontinued therapy due to prolonged QT interval. (46) The CDC recently issued a warning about the danger of using nonpharmaceutical chloroquine phosphate, a commercially available chemical for aquarium use, to treat or prevent COVID-19.  Hydroxychloroquine with or without azithromycin is not routinely recommended and may be associated with serious adverse events such as prolongation of the QT interval. 

There is potential for fecal-oral SARS-CoV-2 transmission, (1, 4, 6, 23, 43) 

 Cancel all elective/non-urgent procedures (e.g., endoscopy, liver biopsy, transient elastography). (60) Accepted Article  Consider, in the interim, primary prophylaxis with beta blocker therapy instead of screening endoscopy in patients with clinically significant portal hypertension or high risk of decompensation.

 Some procedures may need to be performed, e.g., liver biopsy to rule out rejection or diagnose autoimmune hepatitis, therapeutic paracentesis, transjugular intrahepatic portosystemic shunt and/or endoscopy for variceal bleeding, follow-up band ligation in those with recent variceal bleeding, urgent biliary procedures for symptomatic disease such as cholangitis and sepsis (interventional radiology or endoscopic). 

 Research staff should make efforts to use alternative methods to conduct research visits or perform testing such as check-ins with participants by phone and/or performing research-related lab testing at lab testing centers if feasible.

 Research staff should work remotely, unless their presence is required for the safe conduct of the trial.

 Discuss options for conducting telehealth study visits with clinical research organizations and study sponsors.

 Principal investigators should notify commercial sponsors that opening new nonessential clinical trials and enrolling subjects into ongoing "non-essential" clinical trials should be temporarily postponed.

 Arrange for research medications to be sent to subjects by the study sponsor if the research pharmacy is unavailable.

 Institutional policies on clinical research may be more restrictive and should supersede the recommendations contained here.

 Laboratory/basic science research may also need to be restricted based on local policies.

Although residents and fellows have much to learn from the diagnosis and management of COVID-19, there is widespread concern that the risks of exposing trainees to SARS-CoV-2 may outweigh the benefits. There is also concern about further reducing the already significant PPE shortages by involving trainees in direct patient care. The Accreditation Council for Graduate Medical Education has suspended some activities during the COVID-19 pandemic; however, requirements for adequate resources and training, adequate supervision, and work hour limitations have not changed. (65, 66) Recommendations  Ensure adequate resources including PPE appropriate to the clinical setting for all trainees.

 Assign fellows only to participating sites that ensure the safety of patients and fellows.

 Ensure appropriate supervision of trainees working remotely if they are conducting patient care activities (telephone/telemedicine visits).

 Change all educational conferences to virtual conferences.

This article is protected by copyright. All rights reserved  Consider assigning fellows and other trainees to indirect patient care activities and/or telemedicine visits.

 Consider remote supervision of trainees by concurrently monitoring patient care through appropriate telecommunication technology.

The COVID-19 pandemic has profoundly strained healthcare resources around the world. Minimizing the risk of patient and healthcare worker exposure has been central to our efforts to mitigate the impact of the disease on our ability to continue to provide adequate care to our patients. Growing clinical experience with COVID-19 evaluation and management has identified subsets of patients who may be at higher risk for a more severe disease course. The pandemic has affected patients awaiting liver transplantation due to limited transplant center institutional resources and the possibility of donor-derived infection, which has resulted in longer waiting times. This article provides clinicians caring for patients with chronic liver disease with guidance for how to minimize the impact of the COVID-19 pandemic on their patients' care. The situation is evolving rapidly and these recommendations will need to evolve as well. As we learn more about how the COVID-19 pandemic impacts the care of patients with liver disease, we will update the online document available at https://www.aasld.org/about-aasld/covid-19-resources.

This article is protected by copyright. All rights reserved Accepted Article Table 1 

 Should we decide who is more in need of limited resources, i.e., COVID-19 patients vs. patients in urgent need of liver transplantation? It is impossible to weigh the value of the life of a patient with COVID-19 against that of a patient in need of life-saving liver transplantation. We should not compound the pandemic by risking the lives of patients in need of liver transplantation and our goal should be to ensure that an ICU bed is available for every patient who requires one.

 An argument that has been advanced to justify deferring some transplants is a concern about immunosuppressing patients during the COVID-19 pandemic. However, it is possible that immunosuppressed patients may not be at increased risk for severe Nevertheless, immunosuppressed patients have higher viral titers and may be more infectious than immunocompetent individuals. (34)  CMS has clarified that transplants fall into Tier 3b and should not be postponed. (32)  Other issues to consider in hospitals with a high prevalence of COVID-19 include the risk of nosocomial transmission during the transplant admission, difficulty obtaining procedures or other resources when complications arise, and limitations on family/caregiver visitation for a postoperative period that often relies on the engagement of caregivers.

 Is there a point at which we need to ration who will receive a liver transplant? If so, we may need to prioritize patients who are most likely to die on the waitlist and defer those who can wait longer.

 These issues are likely to arise in many transplant programs and predominantly center on the need for limited ICU beds, ventilators, and blood products. Each program will need to establish its institutional capacity to perform liver transplantation and a process for determining whether or not to proceed when an organ is available.

 These decisions should ideally be made in consultation with local medical ethics committees. (2) Accepted Article 

Clinical characteristics of Coronavirus Disease 2019 in China

How should U.S. hospitals prepare for Coronavirus Disease 2019 (COVID-19)?

COVID-19): Cleaning and disinfection for community facilities

Evidence for gastrointestinal infection of SARS-CoV-2

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

SARS-CoV-2-positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19

COVID-19 and Italy: What next? Lancet

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Accepted Article This article is protected by copyright. All rights reserved

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Clinical features of COVID-19 related liver damage

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Liver injury during highly pathogenic human coronavirus infections

Liver injury in COVID-19: Management and challenges

COVID-19 presenting as acute hepatitis

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

SARS-CoV-2 infection in children

Accepted Article This article is protected by copyright. All rights reserved

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: A preliminary analysis

COVID-19): Groups at higher risk for severe illness

Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 -United States

Presumed asymptomatic carrier transmission of COVID-19

Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China

Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis

Centers for Disease Control and Prevention. Interim guidance for healthcare facilities: Preparing for community transmission of COVID-19 in the United States

United Network for Organ Sharing. COVID-19 and solid organ transplant

Non-emergent, elective medical services, and treatment recommendations

Association of Organ Procurement Organizations

American Society of Transplantation. 2019-nCoV (Coronavirus): FAQs for organ donation and transplantation

Perioperative presentation of COVID-19 disease in a liver transplant recipient

Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance

(ncov)-infection-is-suspected

Accepted Article This article is protected by copyright. All rights reserved

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Compassionate use of remdesivir for patients with severe Covid-19

First case of 2019 novel coronavirus in the United States

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Accepted Article This article is protected by copyright. All rights reserved 47. Federal Laboratory Consortium. CDC warns against using nonpharmaceutical chloroquine phosphate

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Revised information for investigational COVID-19 convalescent plasma

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers

News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-andang

Updated: WHO now doesn't recommend avoiding ibuprofen for COVID-19 symptoms

Liverpool Drug Interaction Group. Liverpool COVID-19 interactions

Consistent detection of 2019 novel coronavirus in saliva

Joint GI Society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers

Surgeon General advises hospitals to cancel elective surgeries

COVID-19: Recommendations for management of elective surgical procedures

Considerations in performing endoscopy during the COVID-19 pandemic

AGA Institute rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic

Joint Gastroenterology Society message: COVID-19 use of personal protective equipment in GI endoscopy

FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: Guidance for industry, investigators, and institutional review boards

All rights reserved 64. National Institutes of Health. Guidance for NIH-funded clinical trials and human subjects studies affected by COVID-19

ACGME response to the coronavirus (COVID-19)

Accreditation Council for Graduate Medical Education. ACGME response to pandemic crisis

Accepted Article